Treatment-induced stress syndromes

Area of Science:

• Pharmacology
• Clinical Trials
• Drug Safety

Background:

• Placebo-controlled trials often assess drug efficacy without fully accounting for potential physical dependence.
• The concept of physical dependence, particularly concerning psychotropic drugs, has a historical context but is often neglected in standard efficacy assessments.
• Current trial designs may not adequately capture the risks associated with drug withdrawal.

Discussion:

• The potential for physical dependence and withdrawal is a critical aspect of drug action that requires greater attention.
• Neglect of physical dependence assessment can lead to an overestimation of a drug's true therapeutic benefit.
• This oversight extends beyond psychotropic medications and should be considered a potential factor for all drugs until proven otherwise.

Key Insights:

• Drug efficacy trials may be flawed by not evaluating physical dependence and withdrawal.
• Physical dependence is a significant, yet often overlooked, characteristic of drug action.
• There is a critical knowledge gap regarding the dependence potential of many therapeutic agents.

Outlook:

• Future research should prioritize studies on new compounds in healthy volunteers to evaluate dependence liability.
• Clinical information on therapeutic agents must acknowledge the current lack of data on physical dependence.
• A comprehensive understanding of drug safety necessitates the inclusion of physical dependence and withdrawal assessments in all drug development phases.